NASDAQ:NKTX Nkarta (NKTX) Stock Price, News & Analysis $2.37 +0.05 (+2.16%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.42 +0.05 (+2.15%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nkarta Stock (NASDAQ:NKTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nkarta alerts:Sign Up Key Stats Today's Range$2.30▼$2.4450-Day Range$1.66▼$2.3752-Week Range$1.31▼$6.63Volume746,326 shsAverage Volume533,165 shsMarket Capitalization$168.34 millionP/E RatioN/ADividend YieldN/APrice Target$13.60Consensus RatingBuy Company Overview Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Read More Nkarta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreNKTX MarketRank™: Nkarta scored higher than 40% of companies evaluated by MarketBeat, and ranked 671st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNkarta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNkarta has only been the subject of 3 research reports in the past 90 days.Read more about Nkarta's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nkarta are expected to decrease in the coming year, from ($1.70) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nkarta's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.43% of the float of Nkarta has been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Nkarta has recently increased by 6.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.43% of the float of Nkarta has been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Nkarta has recently increased by 6.32%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.23 News SentimentNkarta has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nkarta this week, compared to 2 articles on an average week.Search Interest8 people have searched for NKTX on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows2 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nkarta's insider trading history. Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTX Stock News HeadlinesNkarta (NASDAQ:NKTX) Stock Rating Upgraded by Wall Street ZenAugust 19, 2025 | americanbankingnews.comHC Wainwright Issues Pessimistic Outlook for Nkarta EarningsAugust 17, 2025 | americanbankingnews.comGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardware is so essential that the data center industry uses enough of it to stretch around the world 8 times – in a single building! So, if you own Nvidia stock now, you might be well-served to sell those shares and check out this under-the-radar play instead. Or if you missed the boat on Nvidia, this is a rare second chance to target tremendous profit potential as AI data centers spring up in every corner of the world. | InvestorPlace (Ad)Stifel Nicolaus Issues Pessimistic Forecast for Nkarta (NASDAQ:NKTX) Stock PriceAugust 16, 2025 | americanbankingnews.comLeerink Partnrs Brokers Boost Earnings Estimates for NkartaAugust 16, 2025 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Nkarta (NASDAQ:NKTX)August 15, 2025 | americanbankingnews.comNkarta price target lowered to $12 from $14 at StifelAugust 15, 2025 | msn.comNkarta, Inc.: Nkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 13, 2025 | finanznachrichten.deSee More Headlines NKTX Stock Analysis - Frequently Asked Questions How have NKTX shares performed this year? Nkarta's stock was trading at $2.49 at the beginning of 2025. Since then, NKTX stock has decreased by 4.8% and is now trading at $2.37. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.06. When did Nkarta IPO? Nkarta (NKTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO. Who are Nkarta's major shareholders? Nkarta's top institutional shareholders include Wasatch Advisors LP (2.51%), Monaco Asset Management SAM (2.23%), Geode Capital Management LLC (1.70%) and Bank of America Corp DE (1.05%). Insiders that own company stock include Simeon George, Paul J Hastings, David Shook, James Trager, Alicia J Hager and Ralph Brandenberger. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings8/12/2025Today8/24/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NKTX CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Price Target for Nkarta$13.60 High Price Target$18.00 Low Price Target$10.00 Potential Upside/Downside+473.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$108.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-27.74% Return on Assets-22.38% Debt Debt-to-Equity RatioN/A Current Ratio15.67 Quick Ratio15.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book0.47Miscellaneous Outstanding Shares71,030,000Free Float65,059,000Market Cap$168.34 million OptionableOptionable Beta0.72 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:NKTX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.